Neuroscience
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM)
Milestone on Schedule
Tuesday July 5, 8:31 am ET
LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment of the 950 patients with mild-to- moderate Alzheimer's Disease (AD) for its North American Phase III clinical trial for Alzhemed(TM), the Company's investigational product candidate for the treatment of AD. The trial is being conducted in 51 U.S. and 17 Canadian clinical centers across North America. The Company has completed the selection of sites for a similarly sized Phase III clinical trial in Europe and expects to begin patient recruitment in the fall of 2005.
[ ... Read the full press release ... ]
From the Neurochem website:
-
Anthony H. Risser
neuroscience | neuropsychology | brain | alzheimer disease
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model J Neurochem. 2011 Sep; 118(5): 928-38 Authors: Fabbro S, Schaller K, Seeds NW Abstract...
- Alzheimer's: Impaired Beta-amyloid Clearance
From the NIH: Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease 09 December 2010 In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers...
- Alzheimer's Disease: Amyloid Jitteriness
A Bloomberg News report about the state of clinical trials of those Alzheimer's disease candidates in the processes/stages in amyloid levels and amyloid deposition: read article here...
- Fibril Structure And Alzheimer Disease
From a Salk Institute for Biological Studies press release:Released: Fri 11-Nov-2005, 08:55 ET Embargo expired: Mon 14-Nov-2005, 17:00 ET 3-D Structure of Alzheimer's Disease Filament Shows How It Zips Up Peptides Newswise — Researchers...
Neuroscience
Business World: Neurochem's Alzhemed and Alzheimer Disease
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM)
Milestone on Schedule
Tuesday July 5, 8:31 am ET
LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment of the 950 patients with mild-to- moderate Alzheimer's Disease (AD) for its North American Phase III clinical trial for Alzhemed(TM), the Company's investigational product candidate for the treatment of AD. The trial is being conducted in 51 U.S. and 17 Canadian clinical centers across North America. The Company has completed the selection of sites for a similarly sized Phase III clinical trial in Europe and expects to begin patient recruitment in the fall of 2005.
[ ... Read the full press release ... ]
From the Neurochem website:
"About Alzhemed™
Alzhemed™ is an orally administered, small organic molecule that has been specifically designed to modify the course of AD through its anti-amyloid activity. As part of a "disease modifying" novel class of product candidates, Alzhemed™ is expected to act at two levels: in preventing and stopping the formation and the deposition of amyloid fibrils in the brain and in binding to soluble A[beta] protein to reduce the amyloid-induced toxicity on neuronal and brain inflammatory cells associated with amyloid build-up in AD."
-
Anthony H. Risser
neuroscience | neuropsychology | brain | alzheimer disease
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model J Neurochem. 2011 Sep; 118(5): 928-38 Authors: Fabbro S, Schaller K, Seeds NW Abstract...
- Alzheimer's: Impaired Beta-amyloid Clearance
From the NIH: Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease 09 December 2010 In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers...
- Alzheimer's Disease: Amyloid Jitteriness
A Bloomberg News report about the state of clinical trials of those Alzheimer's disease candidates in the processes/stages in amyloid levels and amyloid deposition: read article here...
- Fibril Structure And Alzheimer Disease
From a Salk Institute for Biological Studies press release:Released: Fri 11-Nov-2005, 08:55 ET Embargo expired: Mon 14-Nov-2005, 17:00 ET 3-D Structure of Alzheimer's Disease Filament Shows How It Zips Up Peptides Newswise — Researchers...